Open Label Trial of Autologous Adipose-Derived Stromal Vascular Fraction Cell Injections to Treat Diabetic Peripheral Neuropathy: Safety and Clinical Improvement
This open-label pilot trial demonstrated that local injection of autologous adipose-derived stromal vascular fraction cells is a safe intervention that improved sensory perception thresholds and promoted wound healing in patients with diabetic peripheral neuropathy, warranting further investigation in larger clinical studies.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For millions of people living with diabetes, the disease does more than just raise blood sugar; it quietly erodes the body's ability to feel. This condition, known as diabetic peripheral neuropathy, damages the tiny nerves in the feet, leaving patients unable to sense pain, heat, or the pressure of a pebble in a shoe. Without this protective sensation, minor injuries can go unnoticed, turning into deep, non-healing sores that often lead to infection and, in severe cases, amputation. While doctors can manage blood sugar levels and treat pain, there has been no reliable way to repair the damaged nerves themselves. The body's natural repair mechanisms are often overwhelmed by the constant inflammation and poor blood flow caused by diabetes, leaving patients with a progressive loss of feeling that current medicine cannot reverse.
A team of researchers recently explored a different approach, testing whether the body's own healing cells could be harvested and re-injected to jumpstart nerve recovery. They focused on a mixture of cells found naturally in fat tissue, known as the stromal vascular fraction. Unlike complex laboratory-grown stem cells that require weeks of manufacturing, this mixture can be prepared quickly at the bedside. It contains a variety of cells that help build new blood vessels and calm inflammation, acting as a biological signal to the body to begin repairing damaged tissue. The researchers wanted to see if injecting this mixture directly into the feet of patients with severe nerve damage could restore sensation and heal stubborn wounds, offering a potential new path for a condition that currently has no cure.
The study took place in León, Nicaragua, involving nine adults with type 2 diabetes who had lost all protective sensation in their feet. These patients were unable to feel light touch or vibration, a state that puts them at extreme risk for foot ulcers. Eight of the nine participants also had open, non-healing wounds on their feet that had persisted for at least three months despite standard care. The procedure began with a small, limited liposuction to collect a sample of the patients' own abdominal fat. This fat was then processed in a sterile, closed system right in the hospital room. The team used an enzyme to break down the fat tissue, separating the useful cells from the rest, a process that took less than three hours. The resulting cell mixture, containing millions of the patients' own healing cells, was then injected directly into the feet. The injections were placed in four specific areas: the top of the foot, the deep space under the foot, and along the pathways of the major nerves and blood vessels in the ankle and lower leg. For those with open sores, the cells were also applied around the edges of the wound.
Over the course of a year, the researchers monitored the patients closely to ensure the treatment was safe and to track any changes in their condition. The results showed that the procedure was well-tolerated. The only side effects were mild swelling and pain at the injection sites, which resolved within a few days. There were no severe complications directly caused by the cell injections themselves. However, the study did highlight the severity of the underlying disease. One patient, who entered the trial with a foot already suffering from poor blood flow, experienced a worsening of that condition four weeks later, leading to the loss of skin and the eventual amputation of toes. The medical team determined this was a progression of the patient's existing vascular disease rather than a result of the treatment. Another patient developed a new sore later in the study, but this was attributed to pressure on a different part of the foot, not the injection.
The most significant findings emerged when the researchers measured the patients' ability to feel. Before the treatment, none of the patients could feel light touch or vibration at protective levels. By the twelve-week mark, the seven patients who remained in the study showed clear improvements. Their nerves began to respond to stimuli again. By the end of the forty-eight-week study, three patients had regained normal levels of light touch sensation, and six had regained normal vibration sensitivity. In simple terms, these patients went from being unable to feel a gentle touch to having a protective sense of feeling restored. The treatment also helped heal the difficult wounds. One patient with a massive thirty-two square centimeter ulcer saw it close up completely within eight weeks, while others saw their wounds heal over the following months.
This small, open-label trial suggests that injecting a patient's own fat-derived cells into the foot can be a safe way to potentially reverse nerve damage caused by diabetes. The researchers observed that the treatment appeared to stimulate the body to repair nerves and improve blood flow, leading to a return of sensation and the healing of chronic wounds. While the study was too small to provide definitive proof, and the lack of a control group means the results are preliminary, the safety profile and the dramatic return of sensation in several patients offer a promising signal. The work indicates that this point-of-care approach, which avoids the need for complex laboratory manufacturing, could become a viable strategy for treating a condition that currently leaves many patients with no options other than pain management or amputation. Larger studies will be needed to confirm these findings, but the results provide a tangible hope that the damage to the nerves in diabetic feet might be reversible.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.